B+
Bull case
25%
Probability
Target price
$33.00
Analysis reference price unavailable
Analysis 2026-09-05 · RankAlpha Sentiment Codex
SNDX
SyndaxANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Syndax combines two growing commercial products with increasing Revuforj treatment duration, expanding prescriber opportunity, and multiple clinical expansion paths. Q4 axatilimab data and frontline AML progress provide identifiable upside hooks.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +1.2.
What can break
Analyst revisions, consensus surprise data, and post-earnings market-reaction attribution are unavailable, limiting confidence.
Momentum
13
Value
41
Sentiment
99
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $25.00 · Bull $33.00 · Bear $15.00Analysis 2026-09-05; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-10 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-05 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-10
Investment thesis
As of 2026-09-10
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-10. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $37.55
Why
Momentum13 · Δ7d -5.8
Value41 · Δ7d -0.0
Sentiment99 · Δ7d +1.2
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +1.2.
Contradictions & invalidation
- • Analyst revisions, consensus surprise data, and post-earnings market-reaction attribution are unavailable, limiting confidence.
- • Frontline AML enrollment, trial execution, regulatory timing, or eventual commercial adoption may be slower than expected.
- • The thesis remains event-driven: Q4 clinical data could disappoint, frontline AML execution may take longer than expected, and quarterly new-patient initiation can fluctuate.
Catalyst clock
2026-08-04
Q2 commercial execution
Lead driver: Sentiment · See AI snapshot
Momentum
13
9% active weight
Current posture
7d trendSoftening
Δ7d
-5.8
Δ21d
-0.1
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
99
62% active weight
Current posture
7d trendImproving
Δ7d
+1.2
Δ21d
-4.6
Why this grade
Composite grade A. Momentum 13.2 / Value 41.2 / Sentiment 98.8
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-05. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$25.00
Analysis reference price unavailable
Analysis 2026-09-05 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$15.00
Analysis reference price unavailable
Analysis 2026-09-05 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$1.76B
Beta
0.46
Shares Out
89.3M
P/E (TTM) · Derived
-6.0
P/S (TTM)
15.75
P/FCF (TTM) · Derived
-7.83
Rev YoY
+91.8%
EPS YoY
-33.3%
Gross Margin
+95.8%
Op Margin
-77.0%
Net Debt
-$48.64M
Current Ratio
6.77
As of 2026-09-10 • Updated nightlySource: Internal modelMethods & Data